PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

Trial Details

NCT ID

NCT07472153

Phase

PHASE2 / PHASE3

Sponsor

N.N. Alexandrov National Cancer Centre

Status

RECRUITING

Cancer Type

Cervical Cancer

Interventions

• PD-1 antibody
• PD-L1 antibody
• Chemotherapy and bevacizumab (CT-BEV)

Locations (sample)

• Minsk, Lesnoy, Belarus|53.90019,27.56653

Key Eligibility Criteria

• Age ≥18-≤75 years.
• Histologically confirmed diagnosis.
• One of the forms of the cervical cancer:
• Metastatic cervical cancer (stage IVB according to FIGO (International Federation of Gynaecology and Obstetrics) 2018);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.